<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of alcohol-associated liver disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of alcohol-associated liver disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of alcohol-associated liver disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott L Friedman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Runyon, MD, FAASLD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The pathogenesis of liver disease associated with alcohol ingestion is incompletely understood. What is known is that some patients who chronically abuse alcohol develop liver disease, primarily because the liver metabolizes the majority of ingested ethanol. Furthermore, the metabolism of ethanol is required for hepatic injury to occur, although variations in ethanol metabolism do not completely explain the variable susceptibility to alcohol-associated liver disease.</p><p>This topic review will focus on three issues related to the development of alcoholic liver disease:</p><p class="bulletIndent1"><span class="glyph">●</span>The basic aspects of alcohol metabolism</p><p class="bulletIndent1"><span class="glyph">●</span>The mechanisms that may be responsible for the development of hepatic disease</p><p class="bulletIndent1"><span class="glyph">●</span>The factors that determine the frequency with which alcohol abuse leads to liver disease</p><p></p><p>The different pathologic types of alcohol-associated liver disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ALCOHOL METABOLISM</span><span class="headingEndMark"> — </span>Ethanol is metabolized via several pathways, each of which can contribute to toxicity. The primary hepatic pathway generates acetaldehyde and reduced nicotinamide adenine dinucleotide (NAD)  (<a class="graphic graphic_figure graphicRef61009" href="/z/d/graphic/61009.html" rel="external">figure 1</a>). In addition, accessory inducible microsomal pathways may be responsible for the generation of toxic metabolites from several drugs, while a possible role for gastric ethanol metabolism remains controversial.</p><p>Ethanol is metabolized first in the liver to acetaldehyde; this process occurs in the hepatocyte cytosol via a reaction catalyzed by the enzyme alcohol dehydrogenase (ADH) [<a href="#rid1">1</a>]. There are multiple forms of the dimeric ADH molecule, each comprised of different combinations of subunits encoded by separate gene loci [<a href="#rid2">2</a>]. Polymorphisms of ADH do not predict the susceptibility to alcohol-associated liver disease but could explain variations in blood alcohol levels among individuals ingesting the same amount of ethanol.</p><p>The acetaldehyde that is generated is subsequently metabolized to acetate, a process that occurs in the mitochondria and is catalyzed by a different enzyme, acetaldehyde dehydrogenase (ALDH) [<a href="#rid3">3</a>]. This enzyme, like ADH, has multiple isoforms with differing activities. One of the consequences of excess acetaldehyde is impaired macrophage function, which could contribute to the immune defects associated with alcohol-associated liver disease [<a href="#rid4">4</a>].</p><p>Genetic variability in ALDH accounts for the well described flushing reaction among some Asian individuals who drink alcohol; this reaction resembles the response to alcohol in patients taking <a class="drug drug_general" data-topicid="9379" href="/z/d/drug information/9379.html" rel="external">disulfiram</a>. (See  <a class="medical medical_review" href="/z/d/html/2782.html" rel="external">"Approach to flushing in adults", section on 'Alcohol'</a>.) </p><p>The flushing reaction in Asian individuals is due to relative deficiency of ALDH2 isozyme, which results in the accumulation of acetaldehyde [<a href="#rid5">5</a>]. Although acetaldehyde may be a potential accelerant to liver injury, this risk is generally offset by an aversion to further alcohol-induced flushing. As an example, the rate of alcohol use disorder among Chinese individuals with this genotype is much lower than in those without it; however, a separate reduced genetic risk for alcohol use disorder in this subpopulation cannot be excluded [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3"><span class="h1">GASTRIC METABOLISM OF ALCOHOL</span><span class="headingEndMark"> — </span>The stomach has sufficient ADH activity to metabolize a significant amount of ingested alcohol. A study in 1990 aroused great interest by demonstrating that the metabolism of ingested ethanol in the stomach by gastric ADH was lower in women than men [<a href="#rid7">7</a>]. This was associated with increased levels of ethanol reaching the liver via the portal vein in women. This observation provides a potential explanation for why women seem to have an increased risk of liver injury, compared to men, for a given amount of chronic ethanol consumption. Infection with Helicobacter pylori and gastritis are other factors that can reduce the activity of gastric ADH [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS OF ALCOHOL-INDUCED LIVER INJURY</span><span class="headingEndMark"> — </span>The strongest evidence for alcohol as a cause of liver disease comes from epidemiologic data, not biochemical or clinical studies. As an example, a marked reduction in the number of liver-related deaths was documented in the period after prohibition began in 1916 in the United States [<a href="#rid9">9</a>]. Other data suggest that risk of alcohol-associated liver disease is related to the amount and duration of alcohol abuse [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H5"><span class="h1">ALCOHOL-ASSOCIATED STEATOSIS</span><span class="headingEndMark"> — </span>Several factors contribute to the development of alcohol-associated fatty liver including reduced oxidation of hepatic fatty acids and increased lipogenesis [<a href="#rid11">11</a>]. The altered redox state in the liver induced by alcohol impairs beta-oxidation and tricarboxylic acid cycle activity [<a href="#rid12">12</a>]. Chronic ethanol consumption also increases expression of key lipogenic enzyme regulators, such as sterol regulatory element binding proteins (SREBPs) and SREBP-1 target genes, such as fatty acid synthase, acetyl-coenzyme A carboxylase, and stearoyl-CoA desaturase [<a href="#rid13">13</a>]. Genetic determinants may also drive fat accumulation in those who drink alcohol through the gene encoding PNPLA3, a patatin-like phospholipase [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H6"><span class="h1">ALCOHOL-ASSOCIATED STEATOHEPATITIS</span><span class="headingEndMark"> — </span>Not all patients with steatosis develop steatohepatitis. Several factors may contribute to the development of steatohepatitis including cytokines, oxidative stress, and toxic metabolic products of alcohol.</p><p class="headingAnchor" id="H4011159337"><span class="h2">Immunologic defects</span><span class="headingEndMark"> — </span>The innate immune system is increasingly implicated in the liver's response to alcohol [<a href="#rid15">15</a>]. As an example, dendritic cell function may be altered in alcoholic liver disease, an effect that could impair the cell-mediated response to chronic hepatitis C virus infection [<a href="#rid16">16-18</a>]. Altered dendritic function may also lead to increased release of proinflammatory cytokines [<a href="#rid19">19</a>]. Another study identified reduced expression of a glucocorticoid-induced leucine zipper (GILZ) protein, which amplifies macrophage responses and sensitivity to lipopolysaccharide [<a href="#rid20">20</a>]. Inflammasome activation has emerged as a major pathway mediating signals associated with alcohol-induced liver injury. (See <a class="local">'Endotoxin'</a> below.)</p><p>More broadly, activation of innate immunity is thought to amplify inflammation, with engagement of several inflammatory cell types, including neutrophils, macrophages, natural killer cells, natural killer T cells, dendritic cells, as well as T lymphocytes [<a href="#rid21">21</a>]. As macrophages respond to alcohol-associated liver injury, they undergo profound metabolic reprogramming, including phagocytosis, apoptotic regulation, and arachidonic acid metabolism, among others [<a href="#rid22">22</a>]. At the same time, as disease progresses the antigen-presenting capacity of liver immune cells is diminished, rendering patients more susceptible to infections. While these important observations advance our understanding of alcohol-associated liver disease pathogenesis, they have not yet been directly translated into novel diagnostics or therapeutics for patients. </p><p class="headingAnchor" id="H729968114"><span class="h2">Cytokines and inflammation</span></p><p class="headingAnchor" id="H8"><span class="h3">Neutrophil infiltration and activation</span><span class="headingEndMark"> — </span>One of the most characteristic pathologic hallmarks of alcohol-associated hepatitis is infiltration of neutrophils, which are generally absent from other forms of inflammatory liver disease, generally in association with an increase in the peripheral neutrophil count [<a href="#rid23">23</a>] (see  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a>). This observation has spawned a vigorous effort to determine if neutrophil infiltration with release of reactive oxygen species and proteases is at least in part responsible for the hepatic disease. Most attention has focused on characterization of mediators, which stimulate chemotaxis, and which might direct migration of neutrophils into regions of alcohol metabolism. </p><p>Studies have implicated both the IL-33 and IL-8 pathways in neutrophil infiltration [<a href="#rid24">24</a>]. Defects in IL-33 activity in patients with alcohol-associated hepatitis could lead to enhanced risk of infection [<a href="#rid24">24</a>]. IL-8 is a member of the chemokine family, and a known neutrophil chemoattractant. Three studies have documented elevated plasma IL-8 levels in patients with alcoholic hepatitis [<a href="#rid23">23,25,26</a>]. The plasma IL-8 levels correlated with the severity of hepatic injury [<a href="#rid23">23</a>], and IL-8 has been identified immunohistochemically in the liver in patients with alcohol use disorder (AUD). Whether IL-8 is produced locally in the liver and is required for injury to occur are unproven.</p><p>In addition to IL-8, increasing attention focuses on other chemokines as significant drivers of alcohol-associated disease. Macrophage migration inhibitory factor (MIF) has been identified as a central coordinator that orchestrates a broad chemokine response in alcohol-associated hepatitis, based on both human and animal studies [<a href="#rid27">27</a>]. Moreover, this response is unique to alcohol-associated liver disease and not seen in hepatitis C virus infection. Regulation of chemokine and cytokine gene expression in this response is complex and involves genetic as well as epigenetic levels of control [<a href="#rid28">28,29</a>].</p><p>An animal study suggested that hepatic stellate cells may promote steatohepatitis through their membrane receptor neuropilin-1 (NRP-1), which leads to enhanced lgfbp3 (an insulin-binding growth factor) [<a href="#rid30">30</a>]. Lgfbp3 promotes lipid accumulation in hepatocytes, which is antagonized by the protease inhibitor SerpinA12. Interestingly, in patients with alcohol-induced steatohepatitis, serum levels of lgfbp3 are increased while those of SerpinA12 are decreased [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H601152869"><span class="h3">Antigenic adduct formation</span><span class="headingEndMark"> — </span>Acetaldehyde and hydroxyethyl radicals are both derived from the oxidation of ethanol; they bind covalently to proteins, thereby forming adducts that are antigenic. Acetaldehyde, for example, is a highly reactive molecule that can bind avidly to the epsilon amino group of internal lysine residues and the alpha amino N-terminal amino acids of proteins, creating acetaldehyde-protein adducts via a Schiff base mechanism [<a href="#rid31">31</a>]. A number of potential intracellular protein targets have been proposed, including tubulin (a cytoskeletal protein) and collagen, a major component of the hepatic extracellular matrix. There are at least two potentially important consequences of adduct formation.</p><p class="bulletIndent1"><span class="glyph">●</span>Adducts could form with intracellular proteins that are critical to cellular function, leading to dysfunction [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acetaldehyde protein adducts may serve as neoantigens, provoking both cell-mediated and humoral immune responses to attack cells bearing these compounds [<a href="#rid33">33</a>]. This possibility could explain the large number of immunologic features long recognized in many patients with alcohol-associated liver injury [<a href="#rid34">34</a>]. Several studies, for example, have identified antibodies in the serum of patients with AUD which are reactive to acetaldehyde adducts; however, this observation does not easily explain how the antibodies might attack an intracellular protein. In addition, acetaldehyde-protein adducts have also been detected in patients with nonalcohol-associated liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acetaldehyde can also impair macrophage function [<a href="#rid4">4</a>]. (See <a class="local">'Alcohol metabolism'</a> above.)</p><p></p><p>Hydroxyethyl radical adducts also may play an important role in the pathogenesis of alcohol-induced liver injury [<a href="#rid35">35</a>]. In one report, animals given ethanol in vivo generated hydroxyethyl adducts on the external surface of hepatocytes that were recognized by antihydroxyethyl radical adduct antibodies that were present in the sera of patients with cirrhosis. In the presence of monocytes, this antigen-antibody complex was able to trigger a cell-mediated cytotoxic reaction that killed the hepatocytes.</p><p>A toxic metabolite of lipid peroxidation, acrolein, can form covalent protein adducts if not cleared through conjugation to glutathione, in turn provoking endoplasmic reticulum stress that leads to cell damage and death [<a href="#rid36">36</a>]. Scavenging of acrolein by <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> can attenuate experimental alcohol-induced liver injury.</p><p>Available data does not definitively establish if adducts have a pathogenic role or are simply an epiphenomenon of alcohol ingestion. Nevertheless, some studies suggest a potentially important mechanism whereby alcohol can induce liver injury that may be amenable to therapeutic intervention.</p><p class="headingAnchor" id="H9"><span class="h3">Endotoxin</span><span class="headingEndMark"> — </span>There is a growing appreciation for the contribution of the gut microbiome to the pathogenesis of alcohol-associated liver disease [<a href="#rid37">37-39</a>]. Elevated levels of endotoxin (lipopolysaccharide [LPS]) have been detected in the blood of patients with AUD and in animal models exposed to alcohol [<a href="#rid40">40</a>], and toll-like receptors, endoplasmic reticulum stress, and the inflammasome are implicated in these responses [<a href="#rid41">41-43</a>]. Endotoxin interacts with LPS-binding protein and binds to CD14, a receptor on the surface of Kupffer cells (liver macrophages). CD14 interacts with toll-like receptor type 4 (TLR4), which is involved in cytokine activation. It has been hypothesized that the increased levels of LPS contribute to the development of alcohol-associated liver disease by stimulating inflammatory cytokines. In support of this hypothesis are experiments in mice in which the LPS-binding protein, CD14 receptor, or TLR4 have been knocked out; all of these models are less likely to develop hepatic injury than wild-type controls when challenged with alcohol [<a href="#rid44">44-46</a>]. In contrast to TLR4, toll-like receptor 3 (TLR3) may attenuate alcohol-induced liver injury [<a href="#rid47">47</a>].</p><p>On the other hand, contradictory data have also been published. One experimental model demonstrated that ethanol-fed animals given infusions of LPS developed increased expression of LPS binding protein [<a href="#rid48">48</a>]. While both pro- and anti-inflammatory cytokines responses were observed, the animals did not develop the net pro-inflammatory cytokine responses observed after acute LPS challenge [<a href="#rid48">48</a>]. This suggests that individuals with AUD might develop tolerance to the chronic exposure to LPS and that LPS exposure may not be a central process in the development of alcohol-associated liver disease.</p><p class="headingAnchor" id="H10"><span class="h3">Injurious cytokines</span><span class="headingEndMark"> — </span>In addition to chemokines, several studies have documented increased levels of the proinflammatory cytokines tumor necrosis factor, interleukin-1 [<a href="#rid43">43</a>] and interleukin-6 [<a href="#rid23">23,49</a>]. These factors have been implicated in the hemodynamic alterations found in patients with cirrhosis. A study has implicated the p90RSK kinase pathway as a mediator of both injury and fibrosis [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/1259.html" rel="external">"Pathogenesis of ascites in patients with cirrhosis"</a>.)</p><p>Inflammatory cytokines also correlate with disease severity and histologic findings [<a href="#rid51">51</a>]. While their role in alcohol-induced liver injury is unproven, evidence is mounting [<a href="#rid52">52</a>]. In one report, the hepatic inflammation and necrosis observed in ethanol-fed rats were significantly decreased by the administration of neutralizing antibodies to tumor necrosis factor-alpha (TNFa), suggesting a role for this cytokine in the pathogenesis of alcohol-induced liver injury [<a href="#rid53">53</a>]. In another study, mice lacking the TNF receptor 1 gene (but not the TNF receptor 2 gene) were protected from the development of liver disease following ethanol ingestion [<a href="#rid54">54</a>]. A related molecule, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), may also contribute to the pathogenesis of steatosis and liver injury [<a href="#rid55">55</a>].</p><p>Interleukin-17A (IL-17) is a pro-inflammatory cytokine that signals through its receptor IL-17RA to activate macrophages and regulate steatosis in the liver, and injury in a number of organs including liver, lung and colon. IL-17 signaling is activated in experimental injury due to alcohol plus the chemical carcinogen diethylnitrosamine and parallels increases in patients with alcohol-induced liver injury. In these ethanol-fed mice, abrogation of IL-17 signaling through genetic depletion or antagonism of IL-17RA prevents the development of hepatocellular carcinomas [<a href="#rid56">56</a>]. The findings are especially relevant because antagonism of IL-17 is already an approved therapy for psoriatic arthritis and is being explored in other chronic inflammatory diseases, including asthma and inflammatory bowel disease. IL-17 may also promote gut inflammation that drives hepatic injury as Th17 cells are increased in the intestine following alcohol intake; moreover, reduction of Th17 cells in the gut through antagonism of sphingosine-1-phosphate signaling can reduce gut and liver inflammation in experimental mouse models [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H11"><span class="h3">COX-2 enzyme</span><span class="headingEndMark"> — </span>In addition to TNF-alpha, a role has emerged for cyclooxygenase 2 (COX-2). This enzyme, which produces prostaglandins, is elevated in experimental alcohol-induced liver injury, raising the possibility that inhibitors may have a therapeutic benefit [<a href="#rid58">58</a>]. Ethanol-fed rats show increased expression by Kupffer cells of cyclooxygenase 2 mRNA, a key enzyme regulating the production of thromboxanes [<a href="#rid59">59,60</a>]. Furthermore, thromboxane inhibitors attenuate some of the pathologic changes in these animals [<a href="#rid60">60</a>]. It is uncertain whether this approach will be clinically useful. (See  <a class="medical medical_review" href="/z/d/html/1233.html" rel="external">"Pathogenesis of hepatic fibrosis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Dietary fat</span><span class="headingEndMark"> — </span>Inflammation may also be influenced by dietary fat. As an example, saturated fat is capable of down-regulating liver injury in experimental alcohol feeding [<a href="#rid58">58</a>]. The identification of a single nucleotide polymorphism in the <em>PNPLA3</em> gene (also called adiponutrin) that heightens the risk of both nonalcoholic [<a href="#rid61">61</a>] and alcohol-associated liver disease [<a href="#rid62">62</a>] has brought attention to the importance of fat metabolism in the pathogenesis of this disease. While the exact mechanism of how this protein, which is a phospholipase, amplifies liver injury is unknown, the findings nonetheless focus attention on lipid homeostasis as a pathogenic component of disease.</p><p class="headingAnchor" id="H13"><span class="h3">Oxidative stress</span><span class="headingEndMark"> — </span>Oxidative stress, damage to cells by reactive oxygen species, remains a major factor in alcohol-induced liver injury and fibrosis [<a href="#rid63">63-65</a>]. Diversion of ethanol to minor pathways of oxidation in heavy drinkers may be a critical determinant of liver injury because these pathways are more likely to generate injurious reactive oxygen intermediates than ADH. The main sources of reactive oxygen species are the mitochondria and CYP2E1 in hepatocytes and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in activated Kuppfer cells [<a href="#rid12">12</a>].</p><p>Chronic alcohol consumption leads to the induction of microsomes (intracellular membrane compartments, such as smooth endoplasmic reticulum) due to spillover from the ADH pathway. The microsomal pathway has been referred to as the microsomal ethanol oxidation system (MEOS) [<a href="#rid66">66</a>]. Induction of specific components of the MEOS, the membrane associated enzyme, cytochrome CYP2E1 has been documented in individuals with AUD [<a href="#rid67">67</a>] and contributes to the generation of oxidative stress [<a href="#rid68">68,69</a>].</p><p>Polymorphisms of CYP2E1 correlate with differences in susceptibility to alcohol-associated liver disease, although a definitive role for polymorphisms in accounting for variable susceptibility to alcohol-associated liver disease remains uncertain [<a href="#rid70">70</a>]. Both ADH and CYP2E1 are more concentrated in the centrizonal region of the hepatic lobule, the area in which alcohol-induced liver injury is most prominent. (See  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a>.)</p><p>Chronic alcohol ingestion also leads to increased inducible nitric oxide synthase (iNOS) levels, which increase nitric oxide production [<a href="#rid71">71</a>]. Nitric oxide reacts with reactive oxygen species to produce toxic compounds within the liver [<a href="#rid12">12</a>]. One reactive species (superoxide) is produced by NADPH oxidase from Kuppfer cells.</p><p>An epigenetic modulator, sirtuin 6 (SIRT6), has been implicated in protecting liver from oxidant stress during alcohol-induced liver injury [<a href="#rid72">72</a>]. In mice with genetic loss of SIRT6, alcohol induces severe inflammation, whereas transgenic animals overexpressing this molecule were protected. The molecule metal regulatory transcription factor (Mtf1) is a functional co-activator of SIRT6 that enhances its activity.</p><p>Another sirtuin, SIRT1, decreases in the livers of aging mice, which may render the livers of these aging animals more sensitive to oxidative stress and injury as well as amplified fibrosis [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H910121985"><span class="h2">MicroRNAs</span><span class="headingEndMark"> — </span>MicroRNAs (noncoding RNA species) are increasingly recognized as modulators of disease in a variety of clinical conditions. Profiling of microRNAs in the liver and serum from patients with alcoholic hepatitis identified several upregulated microRNAs that regulate a range of biologic functions, with the greatest increase seen in microRNA-182, which correlated with disease severity, short-term mortality, and the ductular reaction [<a href="#rid74">74</a>], and in miR-155, which promotes steatosis in hepatocytes and increased TNF-alpha by macrophages [<a href="#rid75">75</a>]. In hepatic stellate cells, increased miR-21, especially through release in extracellular vesicles, can enhance macrophage infiltration [<a href="#rid75">75</a>]. Studies to manipulate microRNA-182 levels in an animal model implicate this molecule in liver inflammation involving biliary ductal cells but not as a direct result of alcohol metabolism. Another down-regulated microRNA is microRNA-122 [<a href="#rid76">76</a>]. MicroRNAs are also increasingly implicated in hepatic fibrosis, especially miR-29 and miR-214 [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H875974206"><span class="h2">Impaired regeneration</span><span class="headingEndMark"> — </span>As liver injury and inflammation persist over years of chronic ethanol ingestion, the liver slowly loses the capacity to regenerate. A comprehensive study has identified the hepatocyte transcription factor, HNF4-alpha, as a key determinant of this response [<a href="#rid76">76</a>]. The liver in alcoholic hepatitis undergoes profound changes in the expression of many liver-enriched transcription factors and a range of liver-specific genes as detailed in a study using single cell RNA sequencing [<a href="#rid77">77</a>]. In particular, upregulation of the Wnt signaling pathway receptor, FZD6, and unique changes in macrophage subsets provide clues to how alcohol affects liver homeostasis. Another key finding in humans in alcohol-associated hepatitis is the activation of the Hippo/Yes-associated protein (YAP) growth regulatory pathway, which leads to increased conversion of hepatocytes to biliary cells and loss of hepatocyte identity, which may impair regeneration [<a href="#rid78">78</a>]. The findings suggest that inhibition of YAP may be a possible therapeutic option; however, such an inhibitor would need to be carefully titrated because the Hippo/YAP signaling pathway also regulates other cell types and tissues.</p><p>An elegant study that sequenced the livers of patients with progressive stages of alcohol-associated liver disease has demonstrated loss of activity of downstream HNF4-alpha gene targets through DNA hypermethylation, which is an epigenetic modification [<a href="#rid76">76</a>]. Deregulation of HNF4-alpha has been ascribed to increased activity of the fibrogenic cytokine transforming growth factor beta 1 (TGFb1). In aggregate, these findings establish a paradigm wherein broad changes in the transcription landscape involving HNF4-alpha account for the progressive functional deterioration of patients with severe alcohol-associated liver disease. The findings nicely complement an earlier study in which forced expression of HNF4-alpha in the liver of rescued rats with severe fibrosis and irreversible liver failure [<a href="#rid79">79</a>]. These findings establish the potential to reprogram the failing liver by re-expressing differentiation factors, but the translation to clinical implementation of such an approach will require that therapy does not increase the risk of liver cancer.</p><p class="headingAnchor" id="H169610705"><span class="h2">Microbiome</span><span class="headingEndMark"> — </span>There has been an increase in our understanding and focus on the microbiome as a determinant of alcohol-associated liver disease, as well as many other non-liver disorders. It makes sense to implicate the microbiome in liver disease because changes in gut bacterial homeostasis and bacterial products affect the liver before any other solid organ through drainage of gut contents into the portal vein. Moreover, advanced liver disease has long been associated with progressively reduced intestinal barrier function, leading to increased permeability that facilitates translocation of intestinal products to the liver. However, methodologies for characterizing the microbiome have yielded major insights into its role in modulating liver disease. For several years, animal models have demonstrated that manipulation of the fecal microbiome in murine alcohol-induced liver injury can alter the extent of injury [<a href="#rid80">80</a>], but this had not yet translated into therapies. In humans, susceptibility to alcohol-associated liver disease has been attributed to the microbiome, in particular through a "cirrhosis dysbiosis ratio" reflecting an imbalance of different bacterial species [<a href="#rid37">37</a>]. In addition to changes in the bacterial composition, studies have also implicated reduced fungal diversity and Candida overgrowth, with production of a pathogenic endotoxin [<a href="#rid81">81,82</a>]. Bacterial dysbiosis is also reflected in specific circulating microbiome signatures in alcoholic hepatitis, raising the possibility of developing diagnostic blood markers to interrogate the microbiome as a therapeutic target [<a href="#rid83">83</a>].</p><p>Another study has linked a specific constituent of the microbiome, <em>Enterococcus faecalis</em>, as a cause of the hepatocyte death and liver injury through the production of a cytolysin [<a href="#rid84">84</a>]. Investigators identified a predominance of this organism in the microbiome of patients with alcoholic hepatitis, but not in patients with no alcohol use or with alcohol use disorder alone, without liver injury. In animal model studies, the investigators ascribed alcohol-induced liver injury specifically to a cytolysin secreted by this bacterium, by demonstrating that clearance of this bacterium using a specific bacteriophage abrogated alcohol-induced liver injury in mice. The findings, if validated, raise the possibility of a new approach to defining the pathogenesis of alcoholic hepatitis with direct therapeutic potential since bacteriophage therapy has already been used for refractory bacterial infections in burn patients [<a href="#rid85">85</a>]. These findings may represent a breakthrough in the understanding, diagnosis, and treatment of alcohol-associated liver disease, and likely other liver disorders as well. Moreover, knowledge in this field is likely to accelerate as technologies to characterize the microbiome continue to advance, which will identify other targets in the microbiome.</p><p>A related study further links<em> Enterococcus faecalis</em> to the complement pathway in alcohol-associated liver disease. Specifically, the complement receptor of immunoglobulin superfamily (CRIg) is expressed on macrophages and binds both complement C3 protein and gram-positive bacteria. CRIg is reduced in livers of patients with alcohol-associated liver disease, and mice deficient in CRIg develop more severe alcohol-induced liver damage while failing to effectively clear <em>Enterococcus faecalis</em> that had translocated from the gut to the liver [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H16"><span class="h1">MECHANISM OF FIBROGENESIS</span><span class="headingEndMark"> — </span>Great progress has been made in the past several years in identifying the cellular sources of extracellular matrix (ECM), or scar protein in alcohol-induced liver injury and in elucidating mechanisms of fibrogenesis. The ECM in fibrotic liver is comprised of several groups of molecules which together gradually form an insoluble scar, remarkably similar to the scar of cutaneous wounds. These components include "interstitial" collagens (types I and III), glycoproteins such as laminin and fibronectin, and proteoglycans such as dermatan and chondroitin sulfate. The composition of the hepatic scar is similar in all forms of fibrosing liver injury, supporting the concept that the fundamental response of the liver to injury is similar whether due to alcohol, drugs, viral infection, or metabolic abnormality (such as hemochromatosis).</p><p>The hepatic stellate cell (also known as Ito cell or lipocyte) is the principal source of the ECM in hepatic fibrosis, including alcohol-associated liver disease [<a href="#rid87">87-89</a>]. In a normal liver, stellate cells are perisinusoidal cells distributed throughout the liver that are important for storing the bulk of hepatic vitamin A. With liver injury, these cells undergo a characteristic "activation" in which they lose vitamin A, proliferate, and become fibrogenic [<a href="#rid87">87</a>]. Stellate cell activation has been documented in both experimental alcohol-induced injury [<a href="#rid90">90</a>] and human alcohol-associated fibrosis [<a href="#rid91">91</a>].</p><p>Development of methods to isolate stellate cells from rat and human liver has greatly advanced our ability to study these cells and understand how they become activated in vivo. In particular, the release of cytokines from neighboring cells (paracrine activation) and alterations in the surrounding cellular microenvironment contribute to activation [<a href="#rid87">87,92</a>]. The major cytokines involved in this process include platelet-derived growth factor (PDGF), transforming growth factor-1, and endothelin-1.</p><p>Mediators unique to alcohol-associated liver injury may also have a role. Acetaldehyde, a metabolite of alcohol, has minor fibrogenic activity towards cultured stellate cells [<a href="#rid93">93</a>], but is unlikely to be a significant stimulant in vivo. Alcohol itself has no effect. However, increasing evidence supports a role for lipid aldehydes, which are unstable products of the interaction between reactive oxygen intermediates and cellular proteins. Free radicals responsible for this action could be a product of ethanol oxidation by the non-ADH microsomal enzyme oxidation system. Two lipid aldehydes in particular, 4-hydroxynonenal and malondialdehyde, are increased in experimental models of alcohol feeding to rodents [<a href="#rid94">94-97</a>], and may have fibrogenic activity. In addition, there may be other less stable intermediates, which act locally to activate stellate cells and stimulate matrix production. As methods for generating and measuring these unstable compounds improve, more information is likely to emerge about their pathogenic role. A more detailed review of hepatic fibrosis appears elsewhere [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/z/d/html/1233.html" rel="external">"Pathogenesis of hepatic fibrosis"</a>.) </p><p>In addition to mechanistic studies, investigators increasingly focus on genetic determinants of the progression of alcohol-associated liver disease to cirrhosis. A large, multicenter genome-wide association study has identified genetic polymorphisms that influence the risk of progression within the genes <em>PNPLA3</em>, <em>HSD17B13,</em> and <em>Fas-associated factor family member 2 (FAF2); </em>all three of their gene products are localized to fat droplets in hepatocytes, suggesting that they may influence both hepatic fat accumulation and injury in individuals with alcohol-associated liver disease [<a href="#rid98">98</a>].</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis of liver disease associated with alcohol ingestion is incompletely understood. What is known is that some patients with alcohol use disorder develop liver disease, primarily because the liver metabolizes the majority of ingested ethanol. Furthermore, the metabolism of ethanol is required for hepatic injury to occur, although variations in ethanol metabolism do not completely explain the variable susceptibility to alcohol-associated liver disease. Increasing evidence points to the microbiome and pathways of immune dysregulation as important determinants of liver injury and fibrosis due to alcohol. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol is metabolized via several pathways, each of which can contribute to toxicity. The primary hepatic pathway generates acetaldehyde and reduced nicotinamide adenine dinucleotide (NAD)  (<a class="graphic graphic_figure graphicRef61009" href="/z/d/graphic/61009.html" rel="external">figure 1</a>). (See <a class="local">'Alcohol metabolism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several factors contribute to the development of alcohol-associated steatosis including reduced oxidation of hepatic fatty acids and increased lipogenesis. (See <a class="local">'Alcohol-associated steatosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not all patients with steatosis develop steatohepatitis. Several factors may contribute to the development of steatohepatitis including genetic determinants (eg, PNPLA3), cytokines, chemokines, oxidative stress, the microbiome and its products, and toxic metabolic products of alcohol. (See <a class="local">'Alcohol-associated steatohepatitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exciting studies have begun to define the contribution of the microbiome and its dysregulation as a risk factor for alcoholic hepatitis, and further demonstrate the potential of manipulating the microbiome as a therapeutic approach. (See <a class="local">'Microbiome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kaplowitz N, Than TA, Shinohara M, Ji C. Endoplasmic reticulum stress and liver injury. Semin Liver Dis 2007; 27:367.</a></li><li><a class="nounderline abstract_t">Lieber CS. Biochemical factors in alcoholic liver disease. Semin Liver Dis 1993; 13:136.</a></li><li><a class="nounderline abstract_t">Wu X, Fan X, Miyata T, et al. Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease. Annu Rev Pathol 2023; 18:411.</a></li><li><a class="nounderline abstract_t">Shiba S, Nakamoto N, Chu PS, et al. Acetaldehyde exposure underlies functional defects in monocytes induced by excessive alcohol consumption. Sci Rep 2021; 11:13690.</a></li><li><a class="nounderline abstract_t">Bosron WF, Ehrig T, Li TK. Genetic factors in alcohol metabolism and alcoholism. Semin Liver Dis 1993; 13:126.</a></li><li><a class="nounderline abstract_t">Enomoto N, Takase S, Yasuhara M, Takada A. Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes. Alcohol Clin Exp Res 1991; 15:141.</a></li><li><a class="nounderline abstract_t">Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990; 322:95.</a></li><li><a class="nounderline abstract_t">Thuluvath P, Wojno KJ, Yardley JH, Mezey E. Effects of Helicobacter pylori infection and gastritis on gastric alcohol dehydrogenase activity. Alcohol Clin Exp Res 1994; 18:795.</a></li><li class="breakAll">Zakim D, Boyer, TD, et al. Alcoholic liver disease. In: Hepatology, a textbook of liver disease, W.B. Saunders, Philadelpphia 1990. p.821.</li><li><a class="nounderline abstract_t">Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci 1975; 252:85.</a></li><li><a class="nounderline abstract_t">Zakim D, Alexander D, Sleisenger MH. The effect of ethanol on hepatic secretion of triglycerides into plasma. J Clin Invest 1965; 44:1115.</a></li><li><a class="nounderline abstract_t">Adachi M, Brenner DA. Clinical syndromes of alcoholic liver disease. Dig Dis 2005; 23:255.</a></li><li><a class="nounderline abstract_t">You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002; 277:29342.</a></li><li><a class="nounderline abstract_t">Lazo M, Bilal U, Mitchell MC, et al. Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population. Clin Gastroenterol Hepatol 2021; 19:2606.</a></li><li><a class="nounderline abstract_t">Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis 2007; 27:339.</a></li><li><a class="nounderline abstract_t">Aloman C, Gehring S, Wintermeyer P, et al. Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology 2007; 132:698.</a></li><li><a class="nounderline abstract_t">Szabo G, Petrasek J, Bala S. Innate immunity and alcoholic liver disease. Dig Dis 2012; 30 Suppl 1:55.</a></li><li><a class="nounderline abstract_t">Petrasek J, Bala S, Csak T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122:3476.</a></li><li><a class="nounderline abstract_t">Laso FJ, Vaquero JM, Almeida J, et al. Chronic alcohol consumption is associated with changes in the distribution, immunophenotype, and the inflammatory cytokine secretion profile of circulating dendritic cells. Alcohol Clin Exp Res 2007; 31:846.</a></li><li><a class="nounderline abstract_t">Hamdi H, Bigorgne A, Naveau S, et al. Glucocorticoid-induced leucine zipper: A key protein in the sensitization of monocytes to lipopolysaccharide in alcoholic hepatitis. Hepatology 2007; 46:1986.</a></li><li><a class="nounderline abstract_t">Li S, Tan HY, Wang N, et al. Recent Insights Into the Role of Immune Cells in Alcoholic Liver Disease. Front Immunol 2019; 10:1328.</a></li><li><a class="nounderline abstract_t">Marentette JO, Wang M, Michel CR, et al. Multi-omics Analysis of Liver Infiltrating Macrophages Following Ethanol Consumption. Sci Rep 2019; 9:7776.</a></li><li><a class="nounderline abstract_t">Sheron N, Bird G, Koskinas J, et al. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 1993; 18:41.</a></li><li><a class="nounderline abstract_t">Artru F, Bou Saleh M, Maggiotto F, et al. IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis. J Hepatol 2020; 72:1052.</a></li><li><a class="nounderline abstract_t">Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology 1993; 18:576.</a></li><li><a class="nounderline abstract_t">Masumoto T, Onji M, Horiike N, Ohta Y. Assay of serum interleukin 8 levels in patients with alcoholic hepatitis. Alcohol Alcohol Suppl 1993; 1A:99.</a></li><li><a class="nounderline abstract_t">Poulsen KL, Fan X, Kibler CD, et al. Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis. JCI Insight 2021; 6.</a></li><li><a class="nounderline abstract_t">Liu M, Cao S, He L, et al. Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Nat Commun 2021; 12:4560.</a></li><li><a class="nounderline abstract_t">Weichselbaum L, Azouz A, Smolen KK, et al. Epigenetic basis for monocyte dysfunction in patients with severe alcoholic hepatitis. J Hepatol 2020; 73:303.</a></li><li><a class="nounderline abstract_t">Arab JP, Cabrera D, Sehrawat TS, et al. Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. J Hepatol 2020; 73:149.</a></li><li class="breakAll">Tuma DJ, Sorrell MF. The role of acetaldehyde adducts in liver injury. In: Alcoholic Liver Disease, Hall P (Ed), Edward Arnold Press, London 1995.</li><li><a class="nounderline abstract_t">Niemelä O, Parkkila S, Ylä-Herttuala S, et al. Covalent protein adducts in the liver as a result of ethanol metabolism and lipid peroxidation. Lab Invest 1994; 70:537.</a></li><li class="breakAll">Bird GL, MacSween RN. Pathogenesis of alcoholic liver disease: Immune mechanisms. In: Alcoholic Liver Disease, Hall P (Ed), Edward Arnold Press, London 1995.</li><li><a class="nounderline abstract_t">Holstege A, Bedossa P, Poynard T, et al. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: localization and association with progression of liver fibrosis. Hepatology 1994; 19:367.</a></li><li><a class="nounderline abstract_t">Clot P, Parola M, Bellomo G, et al. Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol. Gastroenterology 1997; 113:265.</a></li><li><a class="nounderline abstract_t">Chen WY, Zhang J, Ghare S, et al. Acrolein Is a Pathogenic Mediator of Alcoholic Liver Disease and the Scavenger Hydralazine Is Protective in Mice. Cell Mol Gastroenterol Hepatol 2016; 2:685.</a></li><li><a class="nounderline abstract_t">Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 2016; 65:830.</a></li><li><a class="nounderline abstract_t">Schnabl B. Liver capsule: Mechanisms of alcoholic hepatitis. Hepatology 2016; 64:276.</a></li><li><a class="nounderline abstract_t">Torok NJ. Update on Alcoholic Hepatitis. Biomolecules 2015; 5:2978.</a></li><li><a class="nounderline abstract_t">Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987; 4:8.</a></li><li><a class="nounderline abstract_t">Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol 2013; 28 Suppl 1:38.</a></li><li><a class="nounderline abstract_t">Petrasek J, Iracheta-Vellve A, Csak T, et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc Natl Acad Sci U S A 2013; 110:16544.</a></li><li><a class="nounderline abstract_t">Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2016; 64:955.</a></li><li><a class="nounderline abstract_t">Uesugi T, Froh M, Arteel GE, et al. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002; 168:2963.</a></li><li><a class="nounderline abstract_t">Yin M, Bradford BU, Wheeler MD, et al. Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol 2001; 166:4737.</a></li><li><a class="nounderline abstract_t">Uesugi T, Froh M, Arteel GE, et al. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001; 34:101.</a></li><li><a class="nounderline abstract_t">Arendt BM, Ma DW, Simons B, et al. Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. Appl Physiol Nutr Metab 2013; 38:334.</a></li><li><a class="nounderline abstract_t">Järveläinen HA, Fang C, Ingelman-Sundberg M, Lindros KO. Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. Hepatology 1999; 29:1503.</a></li><li><a class="nounderline abstract_t">McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993; 13:170.</a></li><li><a class="nounderline abstract_t">Morales-Ibanez O, Affò S, Rodrigo-Torres D, et al. Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis. Gut 2016; 65:840.</a></li><li><a class="nounderline abstract_t">Colmenero J, Bataller R, Sancho-Bru P, et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 2007; 132:687.</a></li><li><a class="nounderline abstract_t">McClain C, Barve S, Joshi-Barve S, et al. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res 2005; 29:180S.</a></li><li><a class="nounderline abstract_t">Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997; 26:1530.</a></li><li><a class="nounderline abstract_t">Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 117:942.</a></li><li><a class="nounderline abstract_t">Mundt B, Wirth T, Zender L, et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005; 54:1590.</a></li><li><a class="nounderline abstract_t">Ma HY, Yamamoto G, Xu J, et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol 2020; 72:946.</a></li><li><a class="nounderline abstract_t">Chu S, Sun R, Gu X, et al. Inhibition of Sphingosine-1-Phosphate-Induced Th17 Cells Ameliorates Alcohol-Associated Steatohepatitis in Mice. Hepatology 2021; 73:952.</a></li><li><a class="nounderline abstract_t">Nanji AA, Zakim D, Rahemtulla A, et al. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat. Hepatology 1997; 26:1538.</a></li><li><a class="nounderline abstract_t">Nanji AA, Miao L, Thomas P, et al. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology 1997; 112:943.</a></li><li><a class="nounderline abstract_t">Nanji AA, Khwaja S, Rahemtulla A, et al. Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the rat. Gastroenterology 1997; 112:200.</a></li><li><a class="nounderline abstract_t">Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40:1461.</a></li><li><a class="nounderline abstract_t">Tian C, Stokowski RP, Kershenobich D, et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010; 42:21.</a></li><li><a class="nounderline abstract_t">Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35:297.</a></li><li><a class="nounderline abstract_t">Sampey BP, Stewart BJ, Petersen DR. Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase-1/2 activity via 4-hydroxynonenal. J Biol Chem 2007; 282:1925.</a></li><li><a class="nounderline abstract_t">Sastre J, Serviddio G, Pereda J, et al. Mitochondrial function in liver disease. Front Biosci 2007; 12:1200.</a></li><li><a class="nounderline abstract_t">Lieber CS, DeCarli LM. Ethanol oxidation by hepatic microsomes: adaptive increase after ethanol feeding. Science 1968; 162:917.</a></li><li><a class="nounderline abstract_t">Tsutsumi M, Lasker JM, Takahashi T, Lieber CS. In vivo induction of hepatic P4502E1 by ethanol: role of increased enzyme synthesis. Arch Biochem Biophys 1993; 304:209.</a></li><li><a class="nounderline abstract_t">Zima T, Kalousová M. Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcohol Clin Exp Res 2005; 29:110S.</a></li><li><a class="nounderline abstract_t">Dryden GW Jr, Deaciuc I, Arteel G, McClain CJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep 2005; 7:308.</a></li><li><a class="nounderline abstract_t">Tsutsumi M, Takada A, Wang JS. Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease. Gastroenterology 1994; 107:1430.</a></li><li><a class="nounderline abstract_t">Yuan GJ, Zhou XR, Gong ZJ, et al. Expression and activity of inducible nitric oxide synthase and endothelial nitric oxide synthase correlate with ethanol-induced liver injury. World J Gastroenterol 2006; 12:2375.</a></li><li><a class="nounderline abstract_t">Kim HG, Huang M, Xin Y, et al. The epigenetic regulator SIRT6 protects the liver from alcohol-induced tissue injury by reducing oxidative stress in mice. J Hepatol 2019; 71:960.</a></li><li><a class="nounderline abstract_t">Ramirez T, Li YM, Yin S, et al. Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression. J Hepatol 2017; 66:601.</a></li><li><a class="nounderline abstract_t">Blaya D, Coll M, Rodrigo-Torres D, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut 2016; 65:1535.</a></li><li><a class="nounderline abstract_t">Wang X, He Y, Mackowiak B, Gao B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut 2021; 70:784.</a></li><li><a class="nounderline abstract_t">Argemi J, Latasa MU, Atkinson SR, et al. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nat Commun 2019; 10:3126.</a></li><li><a class="nounderline abstract_t">Kim A, Wu X, Allende DS, Nagy LE. Gene Deconvolution Reveals Aberrant Liver Regeneration and Immune Cell Infiltration in Alcohol-Associated Hepatitis. Hepatology 2021; 74:987.</a></li><li><a class="nounderline abstract_t">Bou Saleh M, Louvet A, Ntandja-Wandji LC, et al. Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis. J Hepatol 2021; 75:912.</a></li><li><a class="nounderline abstract_t">Nishikawa T, Bell A, Brooks JM, et al. Resetting the transcription factor network reverses terminal chronic hepatic failure. J Clin Invest 2015; 125:1533.</a></li><li><a class="nounderline abstract_t">Ferrere G, Wrzosek L, Cailleux F, et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol 2017; 66:806.</a></li><li><a class="nounderline abstract_t">Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol 2020; 72:391.</a></li><li><a class="nounderline abstract_t">Yang AM, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest 2017; 127:2829.</a></li><li><a class="nounderline abstract_t">Puri P, Liangpunsakul S, Christensen JE, et al. The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology 2018; 67:1284.</a></li><li><a class="nounderline abstract_t">Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575:505.</a></li><li><a class="nounderline abstract_t">Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 2019; 19:35.</a></li><li><a class="nounderline abstract_t">Duan Y, Chu H, Brandl K, et al. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat Commun 2021; 12:7172.</a></li><li><a class="nounderline abstract_t">Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134:1655.</a></li><li><a class="nounderline abstract_t">Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 2015; 61:1066.</a></li><li><a class="nounderline abstract_t">Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol 2014; 20:17756.</a></li><li><a class="nounderline abstract_t">Tsukamoto H, Gaal K, French SW. Insights into the pathogenesis of alcoholic liver necrosis and fibrosis: status report. Hepatology 1990; 12:599.</a></li><li><a class="nounderline abstract_t">Okanoue T, Burbige EJ, French SW. The role of the Ito cell in perivenular and intralobular fibrosis in alcoholic hepatitis. Arch Pathol Lab Med 1983; 107:459.</a></li><li class="breakAll">Maher JJ, Friedman SL. Pathogenesis of hepatic fibrosis. In: Alcoholic Liver Disease, Hall P (Ed), Edward Arnold Press, London 1995. p.71.</li><li><a class="nounderline abstract_t">Casini A, Cunningham M, Rojkind M, Lieber CS. Acetaldehyde increases procollagen type I and fibronectin gene transcription in cultured rat fat-storing cells through a protein synthesis-dependent mechanism. Hepatology 1991; 13:758.</a></li><li><a class="nounderline abstract_t">Kamimura S, Gaal K, Britton RS, et al. Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: association of lipid peroxidation with liver fibrogenesis. Hepatology 1992; 16:448.</a></li><li><a class="nounderline abstract_t">Kawase T, Kato S, Lieber CS. Lipid peroxidation and antioxidant defense systems in rat liver after chronic ethanol feeding. Hepatology 1989; 10:815.</a></li><li><a class="nounderline abstract_t">Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006; 65:278.</a></li><li><a class="nounderline abstract_t">Purohit V, Brenner DA. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 2006; 43:872.</a></li><li><a class="nounderline abstract_t">Schwantes-An TH, Darlay R, Mathurin P, et al. Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. Hepatology 2021; 73:1920.</a></li></ol></div><div id="topicVersionRevision">Topic 3613 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17979073" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Endoplasmic reticulum stress and liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8337602" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Biochemical factors in alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36270295" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34211048" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acetaldehyde exposure underlies functional defects in monocytes induced by excessive alcohol consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8337601" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Genetic factors in alcohol metabolism and alcoholism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024727" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2248624" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978087" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effects of Helicobacter pylori infection and gastritis on gastric alcohol dehydrogenase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978087" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of Helicobacter pylori infection and gastritis on gastric alcohol dehydrogenase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1096716" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effect of ethanol on hepatic secretion of triglycerides into plasma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508290" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical syndromes of alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12036955" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32882427" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17979071" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Innate immune response and hepatic inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17258730" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23075869" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Innate immunity and alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22945633" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17386065" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chronic alcohol consumption is associated with changes in the distribution, immunophenotype, and the inflammatory cytokine secretion profile of circulating dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046708" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Glucocorticoid-induced leucine zipper: A key protein in the sensitization of monocytes to lipopolysaccharide in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31244862" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recent Insights Into the Role of Immune Cells in Alcoholic Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31123328" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Multi-omics Analysis of Liver Infiltrating Macrophages Following Ethanol Consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325620" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953139" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8359798" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased plasma interleukin-8 concentrations in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7908198" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Assay of serum interleukin 8 levels in patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33945507" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34315876" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145259" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Epigenetic basis for monocyte dysfunction in patients with severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32087348" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32087348" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176892" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Covalent protein adducts in the liver as a result of ethanol metabolism and lipid peroxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176892" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Covalent protein adducts in the liver as a result of ethanol metabolism and lipid peroxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7507463" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: localization and association with progression of liver fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207287" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28119953" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acrolein Is a Pathogenic Mediator of Alcoholic Liver Disease and the Scavenger Hydralazine Is Protective in Mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26642859" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26867027" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Liver capsule: Mechanisms of alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26540078" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Update on Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3571935" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855294" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24052526" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26773297" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884468" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254735" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reduced early alcohol-induced liver injury in CD14-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431739" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23537027" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216135" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8337603" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cytokines and alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25652085" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17258719" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344606" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397994" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10500078" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227360" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31899206" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32418220" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Inhibition of Sphingosine-1-Phosphate-Induced Th17 Cells Ameliorates Alcohol-Associated Steatohepatitis in Mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397995" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041257" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8978360" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18820647" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19946271" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Variant in PNPLA3 is associated with alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11580156" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Oxidative stress-related molecules and liver fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17107949" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase-1/2 activity via 4-hydroxynonenal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17127373" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mitochondrial function in liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4386718" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ethanol oxidation by hepatic microsomes: adaptive increase after ethanol feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323286" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : In vivo induction of hepatic P4502E1 by ethanol: role of increased enzyme synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344594" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Oxidative stress and signal transduction pathways in alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16042916" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical implications of oxidative stress and antioxidant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7926507" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16688828" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Expression and activity of inducible nitric oxide synthase and endothelial nitric oxide synthase correlate with ethanol-induced liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31295533" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The epigenetic regulator SIRT6 protects the liver from alcohol-induced tissue injury by reducing oxidative stress in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27871879" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27196584" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33127832" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31311938" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33619773" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Gene Deconvolution Reveals Aberrant Liver Regeneration and Immune Cell Infiltration in Alcohol-Associated Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34129887" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25774505" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Resetting the transcription factor network reverses terminal chronic hepatic failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27890791" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31606552" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28530644" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intestinal fungi contribute to development of alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29083504" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31723265" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30292481" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34887405" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18471545" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mechanisms of hepatic fibrogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25066777" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hepatic inflammation and fibrosis: functional links and key pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25548474" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pathogenesis of alcoholic liver disease: role of oxidative metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205558" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Insights into the pathogenesis of alcoholic liver necrosis and fibrosis: status report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6688340" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The role of the Ito cell in perivenular and intralobular fibrosis in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6688340" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The role of the Ito cell in perivenular and intralobular fibrosis in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2010171" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Acetaldehyde increases procollagen type I and fibronectin gene transcription in cultured rat fat-storing cells through a protein synthesis-dependent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1639354" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: association of lipid peroxidation with liver fibrogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2807160" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lipid peroxidation and antioxidant defense systems in rat liver after chronic ethanol feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923312" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Alcohol, oxidative stress and free radical damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16502397" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853455" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
